摘要
目的观察重组人血管内皮抑制素(恩度)联合长春瑞滨加顺铂(NP)化疗治疗中晚期非小细胞肺癌疗效及对T细胞亚群、血管内皮生长因子(VEGF)的影响。方法 90例中晚期非小细胞肺癌患者,按治疗方法不同分为观察组和对照组,每组45例。对照组患者单纯进行NP化疗方案治疗,观察组给予恩度联合NP化疗治疗。治疗结束后评判近期临床疗效,并比较治疗前后T细胞亚群、VEGF水平。结果观察组患者的总有效率40.00%和疾病控制率82.22%均高于对照组的17.78%、60.00%,差异具有统计学意义(P<0.05)。治疗后,观察组VEGF、CD3+较治疗前明显下降,对照组VEGF、CD3+、CD4+、CD4/CD8均较治疗前明显下降,差异均具有统计学意义(P<0.05)。治疗后,观察组VEGF明显低于对照组,CD3+、CD4+、CD4/CD8明显高于对照组,差异均具有统计学意义(P<0.05)。结论恩度联合NP化疗方案是治疗中晚期非小细胞肺癌的理想方法 ,恩度能够有效抑制肿瘤生长,改善和稳定患者病情,增强患者免疫功能,协同提高NP化疗的近期疗效,降低疾病复发,减轻NP化疗的免疫抑制。
Objective To observe the efficacy of recombinant human endostatin(Endostar)combined with vinorelbine plus cisplatin(NP)chemotherapy in the treatment of advanced non-small cell lung cancer and its effect on T cell subsets and vascular endothelial growth factor(VEGF).Methods A total of 90 middle and late non-small cell lung cancer patients were divided by different treatment methods into observation group and control group,with 45 cases in each group.The control group was treated with NP chemotherapy,and the observation group was treated with Endostar combined with NP chemotherapy.After the treatment,the shortterm clinical efficacy was evaluated,and the T cell subgroup and the VEGF level were compared before and after treatment.Results The observation group had higher total effective rate as 40.00%and disease control rate as 82.22%than 17.78%and 60.00%in the control group,and their difference was statistically significant(P<0.05).After treatment,the observation group had obviously lower VEGF and CD3+than before treatment,and the control group had obviously lower VEGF,CD3+,CD4+and CD4/CD8 than before treatment.Their difference was statistically significant(P<0.05).After treatment,the observation group had obviously lower VEGF than the control group,and obviously higher CD3+,CD4+and CD4/CD8 than the control group,and their difference was statistically significant(P<0.05).Conclusion Combination of Endostar and NP chemotherapy is an ideal method for the treatment of advanced non-small cell lung cancer.Endostatin can effectively inhibit the growth of tumor,improve and stabilize disease condition of patients,enhance the immune function of patients,improve the shortterm efficacy of collaborative NP chemotherapy,reduce the recurrence of the disease,and relive the immune suppression of NP chemotherapy.
作者
呙月
GUO Yue(Department of Oncology,Hubei Medical College Affiliated Xiangyang First People’s Hospital,Xiangyang 441000,China)
出处
《中国现代药物应用》
2018年第6期97-99,共3页
Chinese Journal of Modern Drug Application
关键词
中晚期非小细胞肺癌
重组人血管内皮抑制素
T细胞亚群
血管内皮生长因子
Middle and late non-small cell lung cancer
Recombinant human endostatin
T cell subsets
Vascular endothelial growth factor
